Serologic response in human papillomavirus-associated invasive cervical cancer.
Serologic response in human papillomavirus-associated invasive cervical cancer.
复制标题
人乳头瘤病毒相关的浸润性宫颈癌的血清学反应。
DOI：
10.1002/ijc.2910550515
复制
发表时间：
1993
影响因子：
6.4
通讯作者：
Shah,KV
中科院分区：
文献类型：
--
作者：
Viscidi,RP;Sun,Y;Tsuzaki,B;Bosch,FX;Muñoz,N;Shah,KV
人乳头瘤病毒(HPV)转化蛋白E6和E7在HPV相关性宫颈癌中均有表达。我们的目标是使用一种检测构象表位抗体的方法来检测宫颈癌患者中HPV-16E6和E7蛋白的抗体。对HPV和宫颈癌两个病例对照研究的血清标本进行了检测。这项研究在哥伦比亚的卡利、南美和西班牙的9个省进行。病例包括HPV-16或其他HPV相关的浸润性宫颈癌患者和HPV-16相关的高度宫颈上皮内瘤变(CIN-3)患者。侵袭性病例和CIN-3病例的对照是没有细胞学异常且年龄和居住国家匹配的妇女。体外翻译蛋白放射免疫沉淀法检测血清中抗HPV-16E6和E7蛋白抗体。E6和E7蛋白抗体在侵袭性病例中分别为56%和43%，在对照组中分别为1.7%和4.1%。在72%的侵袭性病例和5.8%的对照血清中检测到对这两种蛋白的抗体。高抗体反应性和对这两种蛋白的抗体几乎只在侵袭性病例中被发现。CIN-3组E6、E7蛋白抗体阳性率与CIN-3组比较差异无统计学意义。5例HPV-18相关性浸润性宫颈癌患者血清HPV-16E6和E7蛋白抗体均为阴性。HPV-16E6和E7蛋白的抗体似乎部分是HPV相关宫颈癌的病毒特异性和疾病状态特异性标记物。
Human papillomavirus (HPV) transforming proteins E6 and E7 are uniformly expressed in HPV‐associated cervical cancer. Our objective was to measure antibodies to HPV‐16 E6 and E7 proteins in cervical cancer patients using an assay which would detect antibodies to conformational epitopes. Serum specimens obtained from two case‐control studies of HPVs and cervical cancer were tested. The studies were performed in Cali, Colombia, South America and in 9 provinces of Spain. Cases consisted of women with invasive cervical cancer associated with HPV‐16 or other HPV types and women with HPV‐16‐associated high‐grade cervical intra‐epithelial neoplasia (CIN‐3). Controls for invasive cases and CIN‐3 cases were women who had no cytologic abnormalities and who were matched for age and country of residence. Serum antibodies to HPV‐16 E6 and E7 proteins were detected by radio‐immunoprecipitation of in vitro translated proteins. Antibodies to the E6 and E7 protein were observed among 56% and 43%, respectively, of invasive cases and 1.7% and 4.1%, respectively, of controls. Antibodies to either protein were detected in 72% of sera from invasive cases and 5.8% of sera from controls. High antibody reactivity and antibodies to both proteins were found almost exclusively in invasive cases. The frequency of antibodies to the E6 protein and the E7 protein among CIN‐3 cases did not differ significantly from the CIN‐3 controls. Five women with HPV‐18‐associated invasive cervical cancer were negative for serum antibody to HPV‐16 E6 and E7 proteins. Antibodies to HPV‐16 E6 and E7 proteins appear to be partially virus‐specific and disease state‐specific markers of HPV‐associated cervical cancer.